title: Do angiotensin-converting enzyme (ACE) inhibitors enhance the effect of exercise rehabilitation in patients with hypertension and ACE DD and DI genotypes?
abstract: OBJECTIVE
  To test whether pharmacologic angiotensin-converting enzyme (ACE) inhibition in carriers of the ACE DD or DI (D, deletion; I, insertion of 287 base pairs) genotypes can simulate the genetic advantage of the II genotype and thereby enhance the conditioning effects of aerobic exercise.
  
  
  METHODS
  Nonrandomized controlled trial.
  
  
  METHODS
  Pulmonary institute.
  
  
  METHODS
  Twelve sedentary men with controlled hypertension (5 with DD genotype, 7 with DI genotype; age, 53+/-7y) treated by ACE inhibitors (study group) and 10 patients (8 men, 2 women; 2 with DD genotype, 8 with DI genotype; age, 54+/-10y) who were treated by other antihypertensive drugs (controls).
  
  
  METHODS
  Exercise training.
  
  
  METHODS
  Training effect was measured by maximal oxygen uptake (Vo(2)max) anaerobic threshold (Vo(2AT)), and the corresponding work rates (WR) (in watts)-WRmax and WR(AT)-before and after 10 weeks of training.
  
  
  RESULTS
  Vo(2)max increased by a mean of 10% (200mL/min) and WRmax by 14% (25W) in each group (P<.001). Vo(2AT) and WR(AT) tended to increase more in the study group (Vo(2AT): 10% [186+/-35mL/min] vs 5% [100+/-1mL/min]; P<.006; WR(AT): 19% [19+/-2W] vs 12% [11+/-3W]; P<.03; respectively).
  
  
  CONCLUSIONS
  This study did not show an enhancement of exercise-related conditioning by pharmacologic ACE inhibition among hypertensive patients with ACE DD and DI genotypes, comparable to the advantage conferred by the II genotype.
authors.affiliation: Pulmonary Institute, The Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: Yaniv
authors.initials: Y
authors.lastname: Duzli
authors.forename: Ehud
authors.initials: E
authors.lastname: Grossman
authors.forename: Mark
authors.initials: M
authors.lastname: Gaides
authors.forename: Shlomo
authors.initials: S
authors.lastname: Segev
authors.forename: Norit
authors.initials: N
authors.lastname: Gal
authors.forename: Issahar
authors.initials: I
authors.lastname: Ben-Dov
mesh_terms: D015308:Anaerobic Threshold / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015444:Exercise; D017079:Exercise Tolerance / Q000502:physiology; D005260:Female; D017353:Gene Deletion; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000235:genetics* / Q000503:physiopathology / Q000534:rehabilitation*; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000502:physiology; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007703:Peptidyl-Dipeptidase A